Thiolated chitosan-modified PLA-PCL-TPGS nanoparticles for oral chemotherapy of lung cancer

Nanoscale Research Letters

Volumn 8, Issue 1, 2013, Pages

  Jiang, Liqin ^a   Li, Xuemin ^a   Liu, Lingrong ^a   Zhang, Qiqing ^a  

^a INSTITUTE OF BIOMEDICAL ENGINEERING   (China)

Author keywords

Lung cancer; Nanoparticles; Oral chemotherapy; PLA PCL TPGS; Thiolated chitosan

Indexed keywords

BIOLOGICAL ORGANS; CHEMOTHERAPY; CHITOSAN; DISEASES; DRUG DELIVERY; DRUG PRODUCTS; GLYCOPROTEINS; NANOPARTICLES;

CLINICAL PRACTICES; LUNG CANCER; NANOPARTICLE FORMULATION; NANOPARTICLE UPTAKES; PERMEATION PROPERTIES; PLA-PCL-TPGS; THIOLATED CHITOSAN; TOCOPHERYL POLYETHYLENE GLYCOL 1000 SUCCINATES;

SYNTHESIS (CHEMICAL);

EID: 84875199139     PISSN: 19317573     EISSN: 1556276X     Source Type: Journal    
DOI: 10.1186/1556-276X-8-66     Document Type: Article

References (45)

1. Choy H, Park C, Yao M: Current status and future prospects for satraplatin, an oral platinum analogue. Clin Cancer Res 2008, 14(6):1633-1638.
2. Feng SS, Mei L, Anitha P, Gan CW, Zhou W: Poly(lactide)-vitamin E derivative/montmorillonite nanoparticle formulations for the oral delivery of paclitaxel. Biomaterials 2009, 30(19):3297-3306.
3. Kuppens IE, Bosch TM, van Maanen MJ, Rosing H, Fitzpatrick A, Beijnen JH, Schellens JH: Oral bioavailability of paclitaxel in combination with OC144-093 (ONT-093). Cancer Chemother Pharmacol 2005, 55(1):72-78.
4. Sparreboom A, Van Asperen J, Mayer U, Schinkel AH, Smit JW, Meijer DKF, Borst P, Nooijen WJ, Beijnen JH, van Tellingen O: Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine. Proc Natl Acad Sci USA 1997, 94:2031-2035.
5. Wils P, Phung-Ba V, Warnery A, Lechardeur D, Raeissi S, Hidalgo IJ, Scherman D: Polarized transport of paclitaxel and vinblastine mediated by P-glycoprotein in human intestinal epithelial cell monolayers. Biochem Pharmacol 1994, 48:1528-1530.
6. Marre F, Sanderink GJ, de Sousa G, Gaillard C, Martinet M, Rahmani R: Hepatic biotransformation of paclitaxel (Taxol) in vitro: involvement of the CYP3A subfamily in humans. Cancer Res 1996, 56:1296-1302.
7. Shou M, Martinet M, Korzekwa KR, Krausz KW, Gonzalez FJ, Gelboin HV: Role of human cytochrome P450 3A4 and 3A5 in the metabolism of Taxol and its derivatives: enzyme specificity, interindividual distribution and metabolic contribution in human liver. Pharmacogenetics 1998, 8:391-401.
8. Chen HB, Zheng Y, Tian G, Tian Y, Zeng XW, Liu G, Liu KX, Li L, Li Z, Mei L, Huang LQ: Oral delivery of DMAB-modified paclitaxel-loaded PLGA-TPGS nanoparticles for cancer chemotherapy. Nanoscale Research Letters 2011, 6:4.
9. Ikezoe T, Hisatake Y, Takeuchi T, Ohtsuki Y, Yang Y, Said JW, Taguchi H, Koeffler HP: HIV-1 protease inhibitor, ritonavir: a potent inhibitor of CYP3A4, enhanced the anticancer effects of paclitaxel in androgenindependent prostate cancer cells in vitro and in vivo. Cancer Res 2004, 64:7426-7431.
10. Malingré MM, Richel DJ, Beijnen JH, Rosing H, Koopman FJ, Ten Bokkel Huinink WW, Schot ME, Schellens JH: Coadministration of cyclosporine strongly enhances the oral bioavailability of paclitaxel. J Clin Oncol 2001, 19(4):1160-1166.
11. Chen H, Langer R: Oral particulate delivery: status and future trends. Adv Drug Deliv Rev 1998, 34:339-350.
12. Florence AT, Hussain N: Transcytosis of nanoparticle and dendrimer delivery systems: evolving vistas. Adv Drug Deliv Rev 2001, 50(suppl 1):S69-S89.
13. Pandey R, Zahoor A, Sharma S, Khuller GK: Nano-encapsulation of azole antifungals: potential applications to improve oral drug delivery. Int J Pharm 2005, 301:268-276.
14. des Rieux A, Fievez V, Garinot M, Schneider YJ, Préat V: Nanoparticles as potential oral delivery systems of proteins and vaccines: a mechanistic approach. J Control Release 2006, 116(1):1-27.
15. Lee DW, Powers K, Baney R: Physicochemical properties and blood compatibility of acylated chitosan nanoparticles. Carbohydr Polym 2004, 58:371-377.
16. Bernkop-Schnurch A, Hornof M, Zoidl T: Thiolated polymers-thiomers: synthesis and in vitro evaluation of chitosan-2-iminothiolane conjugates. Int J Pharm 2003, 260:229-237.
17. Fernandez-Urrusuno R, Romani D, Calvo P, Vila-Jato JL, Alonso MJ: Development of a freeze-dried formulation of insulin-loaded chitosan nanoparticles intended for nasal administration. STP Pharma Sciences 1999, 9:429-436.
18. Kast CE, Valenta C, Leopold M, Bernkop-Schnurch A: Design and in vitro evaluation of a novel bioadhesive vaginal drug delivery system for clotrimazole. J Control Release 2002, 81:347-354.
19. Saremi S, Atyabi F, Akhlaghi SP, Ostad SN, Dinarvand R: Thiolated thiolated chitosan nanoparticles for enhancing oral absorption of docetaxel: preparation, in vitro and ex vivo evaluation. Int J Nanomedicine 2011, 6:119-128.
20. Pan Y, Li Y, Zhao H, Zheng JM, Xu H, Wei G, Hao JS, Cui FD: Bioadhesive polysaccharide in protein delivery system: thiolated chitosan nanoparticles improve the intestinal absorption of insulin in vivo. Int J Pharm 2002, 249(1-2):139-147.
21. Atyabi F, Talaie F, Dinarvand R: Thiolated chitosan nanoparticles as an oral delivery system for amikacin: in vitro and ex vivo evaluations. J Nanosci Nanotechnol 2009, 9(8):4593-603.
22. Agnihotri SA, Mallikarjuna NN, Aminabhavi TM: Recent advances on thiolated chitosan-based micro-and nanoparticles in drug delivery. J Control Release 2004, 100(1):5-28.
23. Dintaman JM, Silverman JA: Inhibition of P-glycoprotein by D-alphatocopheryl polyethylene glycol 1000 succinate (TPGS). Pharm Res 1999, 16:1550-1556.
24. Ma Y, Zheng Y, Liu K, Tian G, Tian Y, Xu L, Yan F, Huang L, Mei L: Nanoparticles of poly(lactide-co-glycolide)-d-α-tocopheryl polyethylene glycol 1000 succinate random copolymer for cancer treatment. Nanoscale Res Lett 2010, 5(7):1161-1169.
25. Yu L, Bridgers A, Polli J, Vicker A, Long S, Roy A, Winnike R, Coffin M: Vitamin E-TPGS increases absorption flux of an HIV protease inhibitor by enhancing its solubility and permeability. Pharm Res 1999, 16:1812-1817.
26. Youk HJ, Lee E, Choi MK, Lee YJ, Chung JH, Kim SH, Lee CH, Lim SJ: Enhanced anticancer efficacy of alpha-tocopheryl succinate by conjugation with polyethylene glycol. J Control Release 2005, 107:43-52.
27. Constantinou C, Papas A, Constantinou AI: Vitamin E and cancer: an insight into the anticancer activities of vitamin E isomers and analogs. Int J Cancer 2008, 123(4):739-752.
28. Neuzil J, Tomasetti M, Zhao Y, Dong LF, Birringer M, Wang XF, Low P, Wu K, Salvatore BA, Ralph SJ: Vitamin E analogs, a novel group of "mitocans, " as anticancer agents: the importance of being redox-silent. Mol Pharmacol 2007, 71(5):1185-1199.
29. Gu H, Song C, Long D, Mei L, Sun H: Controlled release of recombinant human nerve growth factor (rhNGF) from poly[(lactic acid)-co-(glycolic acid)] microspheres for the treatment of neurodegenerative disorders. Polym Int 2007, 56:1272-1280.
30. Mei L, Zhang Y, Zheng Y, Tian G, Song C, Yang D, Chen H, Sun H, Tian Y, Liu K, Li Z, Huang L: A novel paclitaxel-loaded poly (ε-caprolactone)/ pluronic F68 nanoparticle overcoming multidrug resistance for breast cancer treatment. Nanoscale Res Lett 2009, 4:1530-1539.
31. Mei L, Sun H, Jin X, Zhu D, Sun R, Zhang M, Song C: Modified paclitaxelloaded nanoparticles for inhibition of hyperplasia in a rabbit arterial balloon injury model. Pharm Res 2007, 24(5):955-962.
32. Ma Y, Huang LQ, Song CX, Zeng XW, Liu G, Mei L: Nanoparticle formulation of poly(ε-caprolactone-co-lactide)-d-α-tocopheryl polyethylene glycol 1000 succinate random copolymer for cervical cancer treatment. Polymer 2010, 51:5952-5959.
33. Barr WH, Riegelman S: Intestinal drug absorption and metabolism. I. Comparison of methods and models to study physiological factors of in vitro and in vivo intestinal absorption. J Pharm Sci 1970, 59(2):154-163.
34. Hosseinzadeh H, Atyabi F, Dinarvand R, Ostad SN: Chitosan-pluronic nanoparticles as oral delivery of anticancer gemcitabine: preparation and in vitro study. Int J Nanomedicine 2012, 7:1851-1863.
35. Florence AT: Nanoparticle uptake by the oral route: fulfilling its potential? Drug Discov Today 2005, 2:75-81.
36. Norris DA, Puri N, Sinko PJ: The effect of physical barriers and properties on the oral absorption of particulates. Adv Drug Deliv Rev 1998, 34(2-3):135-154.
37. Hariharan S, Bhardwaj V, Bala I, Sitterberg J, Bakowsky U, Ravi Kumar MN: Design of estradiol loaded PLGA nanoparticulate formulations: a potential oral delivery system for hormone therapy. Pharm Res 2006, 23:184-196.
38. Artursson P, Palm K, Luthman K: Caco-2 monolayers in experimental and theoretical predictions of drug transport. Adv Drug Deliv Rev 2001, 46:27-43.
39. Nabholtz JM, Tonkin K, Smylie M, Au HJ, Lindsay MA, Mackey J: Chemotherapy of lung cancer: are the taxanes going to change the natural history of lung cancer? Expert Opin Pharmacother 2000, 1(2):187-206.
40. Yan F, Zhang C, Zheng Y, Mei L, Tang L, Song C, Sun H, Huang L: The effect of poloxamer 188 on nanoparticle morphology, size, cancer cell uptake, and cytotoxicity. Nanomedicine 2010, 6(1):170-178.
41. Leroueil PR, Hong S, Mecke A, Baker JR Jr, Orr BG, Banaszak Holl MM: Nanoparticle interaction with biological membranes: does nanotechnology present a Janus face? Acc Chem Res 2007, 40:335-342.
42. Song C, Labhasetwar V, Cui X, Underwood T, Levy RJ: Arterial uptake of biodegradable nanoparticles for intravascular local drug delivery: results with an acute dog model. J Control Release 1998, 54(2):201-211.
43. Bhardwaj V, Ankola DD, Gupta SC, Schneider M, Lehr CM, Kumar MN: PLGA nanoparticles stabilized with cationic surfactant: safety studies and application in oral delivery of paclitaxel to treat chemical-induced breast cancer in rat. Pharm Res 2009, 26(11):2495-2503.
44. Zhang Y, Tang L, Sun L, Bao J, Song C, Huang L, Liu K, Tian Y, Tian G, Li Z, Sun H, Mei L: A novel paclitaxel-loaded poly (ε-caprolactone)/poloxamer 188 blend nanoparticle overcoming multidrug resistance for cancer treatment. Acta Biomater 2010, 6(6):2045-2052.
45. Hasegawa M, Yagi K, Iwakawa S, Hirai M: Thiolated chitosan induces apoptosis via caspase-3 activation in lung tumor cells. Jpn J Cancer Res 2001, 92(4):459-466.